-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130

Benzinga·08/05/2026 13:52:50
Listen to the news
Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $115 to $130.